Artivion (NYSE:AORT) Research Coverage Started at JMP Securities

JMP Securities started coverage on shares of Artivion (NYSE:AORT) in a report issued on Wednesday, MarketBeat reports. The firm issued an outperform rating and a $33.00 price target on the stock.

A number of other brokerages have also recently weighed in on AORT. Oppenheimer boosted their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Finally, Lake Street Capital boosted their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $30.60.

Artivion Trading Down 0.5 %

Shares of NYSE:AORT opened at $26.47 on Wednesday. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $1.10 billion, a PE ratio of -110.29 and a beta of 1.74. Artivion has a 1 year low of $12.16 and a 1 year high of $29.24. The firm has a fifty day moving average price of $25.90 and a 200 day moving average price of $24.64.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The business had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Analysts expect that Artivion will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Artivion news, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Matthew A. Getz sold 9,420 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total value of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares of the company’s stock, valued at $863,475.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,109 shares of company stock valued at $951,935 in the last ninety days. Company insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AORT. Creative Planning raised its holdings in shares of Artivion by 182.1% in the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after buying an additional 18,486 shares in the last quarter. SG Americas Securities LLC bought a new stake in Artivion in the third quarter valued at $450,000. Perceptive Advisors LLC raised its stake in Artivion by 4.7% during the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after acquiring an additional 124,725 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Artivion by 3.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after purchasing an additional 481 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Artivion in the 2nd quarter worth about $366,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.